Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab
Background: To investigate visual and anatomical outcomes in eyes with exudative age-related macular degeneration treated with intravitreal aflibercept following prior treatment with intravitreal ranibizumab. Materials and Methods: Retrospective, single-center study of 192 eyes treated with 0.5 mg i...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2015-01-01
|
| Series: | Indian Journal of Ophthalmology |
| Subjects: | |
| Online Access: | http://www.ijo.in/article.asp?issn=0301-4738;year=2015;volume=63;issue=11;spage=832;epage=836;aulast=Narayan |
| _version_ | 1818033627359870976 |
|---|---|
| author | Daniel Sanju Narayan James Muecke |
| author_facet | Daniel Sanju Narayan James Muecke |
| author_sort | Daniel Sanju Narayan |
| collection | DOAJ |
| description | Background: To investigate visual and anatomical outcomes in eyes with exudative age-related macular degeneration treated with intravitreal aflibercept following prior treatment with intravitreal ranibizumab. Materials and Methods: Retrospective, single-center study of 192 eyes treated with 0.5 mg intravitreal ranibizumab every 4 weeks for three consecutive doses followed by a variable dose schedule. After more than 12 months of ranibizumab treatment, eyes that required ranibizumab injections at 4-week or 6-week intervals were switched to aflibercept therapy. Results: After 12-69 months (42 months ± 18 months, mean ± standard deviation [SD]) of treatment with intravitreal ranibizumab, 80 eyes were changed to 2 mg intravitreal aflibercept treatment with follow-up after 12-18 months (16 months ± 1 month, mean ± SD). Thirty-nine eyes had persistent macular fluid after treatment with ranibizumab. Mean logMAR visual acuity (VA) in eyes treated with ranibizumab changed by − 0.089 ± 0.310 (mean ± SD; P = 0.0003), which correlates to an approximate gain of 4.5 letters. The number of eyes with macular fluid decreased from 39 to 23 after aflibercept treatment. Mean logMAR VA in eyes with intraretinal macular fluid treated with aflibercept changed by −0.079 ± 0.134 (mean ± SD; P = 0.006), which correlates to an approximate gain of 4 letters. Mean logMAR VA in eyes with submacular fluid was not significantly different after aflibercept treatment. Conclusion: Eyes with persistent intraretinal macular fluid had visual and anatomic response after changing from ranibizumab to aflibercept treatment. |
| first_indexed | 2024-12-10T06:26:16Z |
| format | Article |
| id | doaj.art-f658da1e16bc4752b71706df65f368be |
| institution | Directory Open Access Journal |
| issn | 0301-4738 1998-3689 |
| language | English |
| last_indexed | 2024-12-10T06:26:16Z |
| publishDate | 2015-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Ophthalmology |
| spelling | doaj.art-f658da1e16bc4752b71706df65f368be2022-12-22T01:59:13ZengWolters Kluwer Medknow PublicationsIndian Journal of Ophthalmology0301-47381998-36892015-01-01631183283610.4103/0301-4738.171964Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumabDaniel Sanju NarayanJames MueckeBackground: To investigate visual and anatomical outcomes in eyes with exudative age-related macular degeneration treated with intravitreal aflibercept following prior treatment with intravitreal ranibizumab. Materials and Methods: Retrospective, single-center study of 192 eyes treated with 0.5 mg intravitreal ranibizumab every 4 weeks for three consecutive doses followed by a variable dose schedule. After more than 12 months of ranibizumab treatment, eyes that required ranibizumab injections at 4-week or 6-week intervals were switched to aflibercept therapy. Results: After 12-69 months (42 months ± 18 months, mean ± standard deviation [SD]) of treatment with intravitreal ranibizumab, 80 eyes were changed to 2 mg intravitreal aflibercept treatment with follow-up after 12-18 months (16 months ± 1 month, mean ± SD). Thirty-nine eyes had persistent macular fluid after treatment with ranibizumab. Mean logMAR visual acuity (VA) in eyes treated with ranibizumab changed by − 0.089 ± 0.310 (mean ± SD; P = 0.0003), which correlates to an approximate gain of 4.5 letters. The number of eyes with macular fluid decreased from 39 to 23 after aflibercept treatment. Mean logMAR VA in eyes with intraretinal macular fluid treated with aflibercept changed by −0.079 ± 0.134 (mean ± SD; P = 0.006), which correlates to an approximate gain of 4 letters. Mean logMAR VA in eyes with submacular fluid was not significantly different after aflibercept treatment. Conclusion: Eyes with persistent intraretinal macular fluid had visual and anatomic response after changing from ranibizumab to aflibercept treatment.http://www.ijo.in/article.asp?issn=0301-4738;year=2015;volume=63;issue=11;spage=832;epage=836;aulast=NarayanAfliberceptage-related macular degenerationchoroidal neovascularizationintraretinal fluidranibizumabsubretinal fluid |
| spellingShingle | Daniel Sanju Narayan James Muecke Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab Indian Journal of Ophthalmology Aflibercept age-related macular degeneration choroidal neovascularization intraretinal fluid ranibizumab subretinal fluid |
| title | Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab |
| title_full | Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab |
| title_fullStr | Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab |
| title_full_unstemmed | Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab |
| title_short | Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab |
| title_sort | intravitreal aflibercept treatment in eyes with exudative age related macular degeneration following prior treatment with intravitreal ranibizumab |
| topic | Aflibercept age-related macular degeneration choroidal neovascularization intraretinal fluid ranibizumab subretinal fluid |
| url | http://www.ijo.in/article.asp?issn=0301-4738;year=2015;volume=63;issue=11;spage=832;epage=836;aulast=Narayan |
| work_keys_str_mv | AT danielsanjunarayan intravitrealaflibercepttreatmentineyeswithexudativeagerelatedmaculardegenerationfollowingpriortreatmentwithintravitrealranibizumab AT jamesmuecke intravitrealaflibercepttreatmentineyeswithexudativeagerelatedmaculardegenerationfollowingpriortreatmentwithintravitrealranibizumab |